このページの翻訳は実験的なもので、現在開発中です。お待ちしております

BridgeBio Pharma マネジメント

マネジメント基準チェック /24

BridgeBio Pharma'sの CEO はNeil Kumarで、 Apr2015年に任命され、の在任期間は 9.17年です。の年間総報酬は$ 12.16Mで、 6.1%給与と93.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の3.69%を直接所有しており、その価値は$ 188.05M 。経営陣と取締役会の平均在任期間はそれぞれ5.4年と4.4年です。

主要情報

Neil Kumar

最高経営責任者

US$12.2m

報酬総額

CEO給与比率	6.1%
CEO在任期間	9.4yrs
CEOの所有権	3.7%
経営陣の平均在職期間	5.2yrs
取締役会の平均在任期間	4.7yrs

経営陣の近況

Recent updates

Revenues Not Telling The Story For BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Sep 24

BridgeBio: With HELIOS-B Overhang Removed, Focus To Turn To Approval And Launch Of Acoramidis

Aug 31

BridgeBio Pharma's Acoramidis Leads Promising Pipeline With FDA Approval On Horizon

Aug 17

BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing

Jun 10

BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing

Jul 02

New Forecasts: Here's What Analysts Think The Future Holds For BridgeBio Pharma, Inc. (NASDAQ:BBIO)

May 09

Time To Worry? Analysts Just Downgraded Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Outlook

Feb 28

Analysts Just Made A Major Revision To Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Revenue Forecasts

Jan 09

BridgeBio stock rises as BBP-398, Lumakras combo for lung cancer gets FDA fast track status

Oct 11

BridgeBio, Sentynl's Nulibry for rare disorder in children gets approval in EU

Sep 20

BridgeBio Pharma: Down But Not Out

Aug 31

BridgeBio starts dosing in phase 1 trial of BBP-671 for metabolic disorders

Aug 18

CEO報酬分析

BridgeBio Pharma の収益と比較して、Neil Kumar の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$454m
Mar 31 2024	n/a	n/a	-US$538m
Dec 31 2023	US$12m	US$742k	-US$643m
Sep 30 2023	n/a	n/a	-US$613m
Jun 30 2023	n/a	n/a	-US$573m
Mar 31 2023	n/a	n/a	-US$425m
Dec 31 2022	US$7m	US$1m	-US$481m
Sep 30 2022	n/a	n/a	-US$491m
Jun 30 2022	n/a	n/a	-US$509m
Mar 31 2022	n/a	n/a	-US$596m
Dec 31 2021	US$26m	US$725k	-US$563m
Sep 30 2021	n/a	n/a	-US$535m
Jun 30 2021	n/a	n/a	-US$495m
Mar 31 2021	n/a	n/a	-US$520m
Dec 31 2020	US$10m	US$550k	-US$449m
Sep 30 2020	n/a	n/a	-US$402m
Jun 30 2020	n/a	n/a	-US$346m
Mar 31 2020	n/a	n/a	-US$291m
Dec 31 2019	US$26m	US$503k	-US$261m
Sep 30 2019	n/a	n/a	-US$226m
Jun 30 2019	n/a	n/a	-US$197m
Mar 31 2019	n/a	n/a	-US$155m
Dec 31 2018	US$450k	US$450k	-US$131m

報酬と市場: Neilの総報酬 ($USD 12.16M ) は、 US市場 ($USD 8.44M ) の同規模の企業の平均を上回っています。

報酬と収益: Neilの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Neil Kumar (45 yo)

9.4yrs

在職期間

US$12,158,626

報酬

Dr. Neil Kumar, Ph D., has been Director of Lianbio since October 2019. He is a Co-Founder of BridgeBio Pharma, Inc. and serves as its Chief Executive Officer and Director since April 2015.He served as Pr...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Neil Kumar	Co-Founder	9.4yrs	US$12.16m	3.67% $ 172.2m
Charles Homcy	Co-Founder	no data	US$1.11m	0.65% $ 30.7m
Frank McCormick	Co-Founder	no data	US$1.74m	0.59% $ 27.4m
Brian Stephenson	CFO & Secretary	5.9yrs	US$6.65m	0.045% $ 2.1m
Richard Scheller	Chairman of Research & Development	5.7yrs	US$2.01m	データなし
Thomas Trimarchi	President & COO	less than a year	データなし	0.20% $ 9.4m
Uma Sinha	Chief Scientific Officer	8.4yrs	US$2.75m	データなし
Grace Rauh	Vice President of Communications	no data	データなし	データなし
Eli Wallace	Chief Scientific Officer of Oncology	4.8yrs	データなし	データなし
Eric David	Chief Executive Officer of Gene Therapy	no data	データなし	データなし
Matthew Outten	Chief Commercial Officer	3.3yrs	データなし	データなし
Adora Ndu	Chief Regulatory Affairs Officer	2.7yrs	データなし	データなし

5.2yrs

平均在職期間

54.5yo

平均年齢

経験豊富な経営陣: BBIOの経営陣は経験豊富で経験豊富です（平均在職期間は5.4年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Neil Kumar	Co-Founder	9.4yrs	US$12.16m	3.67% $ 172.2m
Charles Homcy	Co-Founder	5.8yrs	US$1.11m	0.65% $ 30.7m
Frank McCormick	Co-Founder	less than a year	US$1.74m	0.59% $ 27.4m
Fred Hassan	Independent Director	3.1yrs	US$600.00k	0.010% $ 481.1k
Ronald Daniels	Independent Director	4.6yrs	US$600.00k	0.0055% $ 259.3k
Eric Aguiar	Independent Director	5.5yrs	US$600.00k	0% $ 0
Randal Scott	Independent Director	4.3yrs	US$600.00k	0.0048% $ 224.6k
Ali Satvat	Independent Director	8.5yrs	US$600.00k	0% $ 0
James Momtazee	Director	8.5yrs	US$600.00k	0.047% $ 2.2m
Jennifer Cook	Director	4.8yrs	US$600.00k	0.0038% $ 178.2k
Wen-Chaun Lo	Independent Director	4.3yrs	US$600.00k	0.13% $ 6.3m
Andrea Ellis	Independent Director	3.1yrs	US$600.00k	0.0064% $ 299.2k

4.7yrs

平均在職期間

62.5yo

平均年齢

経験豊富なボード: BBIOの取締役会は経験豊富であると考えられます ( 4.4年の平均在任期間)。

BridgeBio Pharma マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Co-Founder notifies of intention to sell stock

BridgeBio Pharma, Inc. Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

CFO & Secretary exercised options and sold US$433k worth of stock

BridgeBio Pharma, Inc., Annual General Meeting, Jun 21, 2024

Co-Founder exercised options and sold US$1.8m worth of stock

Co-Founder notifies of intention to sell stock

Recent updates

BridgeBio Pharma, Inc. Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

Revenues Not Telling The Story For BridgeBio Pharma, Inc. (NASDAQ:BBIO)

BridgeBio: With HELIOS-B Overhang Removed, Focus To Turn To Approval And Launch Of Acoramidis

BridgeBio Pharma, Inc. Presents Additional Data from an Analysis of its Phase 3 ATTRibute-CM and Open-Label Extension Study of Acoramidis in ATTR-CM at the European Society of Cardiology 2024

Co-Founder notifies of intention to sell stock

BridgeBio Pharma, Inc. and QED Therapeutics Announce the Launch of the Initial Phase of MyAchonJourney

BridgeBio Pharma's Acoramidis Leads Promising Pipeline With FDA Approval On Horizon

Consensus EPS estimates upgraded to US$2.19 loss, revenue downgraded

New major risk - Financial position

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

BridgeBio Pharma, Inc. Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

BridgeBio Pharma, Inc. Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing

BridgeBio Pharma, Inc. Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia

BridgeBio Pharma: Upping An Existing Position (Rating Upgrade)

Consensus revenue estimates increase by 11%

CFO & Secretary exercised options and sold US$433k worth of stock

Consensus revenue estimates increase by 138%

Consensus revenue estimates increase by 162%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

BridgeBio Pharma, Inc., Annual General Meeting, Jun 21, 2024

BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement

Consensus revenue estimates increase by 83%

BridgeBio Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $250.00001 million.

Consensus revenue estimates increase by 44%

BridgeBio Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $250.00001 million.

BridgeBio Pharma, Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates increase by 81%, EPS downgraded

Full year 2023 earnings: EPS and revenues miss analyst expectations

Co-Founder exercised options and sold US$1.8m worth of stock

New major risk - Financial position

BridgeBio Pharma, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy

BridgeBio Pharma, Inc. Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months

Consensus revenue estimates fall by 25%

BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck

BridgeBio Pharma, Inc. Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy in the New England Journal of Medicine

Co-Founder notifies of intention to sell stock

BridgeBio Pharma, Inc. Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia

Now 22% undervalued after recent price drop

Co-Founder notifies of intention to sell stock

BridgeBio Pharma, Inc. Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Consensus EPS estimates fall by 11%, revenue upgraded

Now 22% undervalued after recent price drop

Estimating The Intrinsic Value Of BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 13%

BridgeBio Pharma, Inc. Shares Positive Long-Term Data from an Ongoing Phase 2 Study, Which Support the Potential Use of Glycosylated Alpha-dystroglycan (DG) Levels as a Surrogate Endpoint in Limb-Girdle Muscular Dystrophy Type 2I/R9

BridgeBio Pharma, Inc. announced that it expects to receive $250.003806 million in funding from Qatar Investment Authority and other investors

Bridgebio Pharma Announces Positive Feedback from the U.S. Fda and Eu Ema on the Regulatory Path for A Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia

BridgeBio Pharma, Inc. Presents Detailed Positive Results from Phase 3 Attribute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) At European Society of Cardiology Congress 2023

Co-Founder notifies of intention to sell stock

New minor risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Bridgebio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-Girdle Muscular Dystrophy Type 2I (Lgmd2i/R9) Based on Glycosylated Alpha-Dystroglycan (Dg) Levels and Announces First Patient Dosed in Fortify Phase 3 Study

Bridgebio Announces Consistently Positive Results from Phase 3 Attribute-Cm Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy

Price target increased by 20% to US$33.90

BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing

BridgeBio Pharma, Inc. Presents Updated Six Month Results from Its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia

CFO & Secretary exercised options and sold US$632k worth of stock

Price target increased by 8.3% to US$28.40

New Forecasts: Here's What Analysts Think The Future Holds For BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Co-Founder notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Co-Founder notifies of intention to sell stock

Consensus revenue estimates increase by 105%

Price target increased by 8.6% to US$23.90

Consensus revenue estimates decrease by 53%, EPS upgraded

Time To Worry? Analysts Just Downgraded Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Outlook

Key Executive notifies of intention to sell stock

マネジメント基準チェック /24